What is the appropriate work‑up and management—including acute and preventive therapies and hormonal considerations—for a 45‑55‑year‑old perimenopausal woman presenting with new‑onset or worsening migraines?

Perimenopause Migraines: Work-Up and Management

Diagnostic Approach

Perimenopausal women presenting with new-onset or worsening migraines require assessment for red-flag features—including thunderclap onset, progressive worsening, focal neurological deficits, fever, or impaired consciousness—that mandate urgent MRI to exclude secondary causes such as stroke or mass lesion. 1 In the absence of red flags, neuroimaging is not required for typical migraine patterns. 2

• Document headache frequency, duration, severity, associated symptoms (nausea, photophobia, phonophobia), and relationship to menstrual cycle using a headache diary. 2
• Screen for medication-overuse headache by quantifying acute medication use; overuse is defined as NSAIDs ≥15 days/month or triptans ≥10 days/month. 2
• Assess modifiable risk factors including obesity, excessive caffeine intake (>200 mg/day), obstructive sleep apnea, psychiatric comorbidities (depression, anxiety), and stress. 1
• Rule out other causes of worsening headache during perimenopause, including hypertension, thyroid dysfunction, and sleep disorders. 3

Pathophysiology and Prognosis

• Fluctuating and falling estrogen levels during perimenopause increase migraine frequency and severity, particularly in women with a history of menstrual migraine. 4, 5, 6
• Women with premenstrual syndrome prior to menopause are more likely to experience increased migraine attacks during late menopausal transition. 4
• Natural menopause is associated with lower migraine incidence compared with surgical menopause; women undergoing bilateral oophorectomy often experience worse disease status. 4, 7, 3
• After natural menopause with complete cessation of menses and stable estrogen levels, many women experience improvement in migraine. 5, 3

Acute Treatment Strategy

For mild-to-moderate attacks, NSAIDs (ibuprofen 400–800 mg, naproxen sodium 500–825 mg) are first-line therapy; for moderate-to-severe attacks or NSAID failure, add a triptan (sumatriptan 50–100 mg, rizatriptan 10 mg) to the NSAID regimen, as this combination is superior to either agent alone. 2

• Take acute medication early in the attack while pain is still mild to maximize effectiveness. 2
• If one triptan fails after 2–3 episodes, try a different triptan (rizatriptan, eletriptan, zolmitriptan, naratriptan), as failure of one does not predict failure of others. 8, 2
• For patients with prominent nausea or vomiting, consider intranasal sumatriptan or subcutaneous sumatriptan 6 mg, which provides the highest efficacy with onset within 15 minutes. 2
• Strictly limit all acute medications to ≤2 days per week (≤10 days per month) to prevent medication-overuse headache, which paradoxically increases headache frequency and can lead to daily headaches. 2
• Never prescribe opioids (codeine, hydrocodone, oxycodone) or butalbital-containing compounds for migraine, as they provide questionable efficacy, carry high dependence risk, and cause rebound headaches. 8, 2

Preventive Therapy Indications

Initiate preventive therapy immediately if the patient experiences ≥2 migraine attacks per month causing disability ≥3 days, or if acute medication use exceeds 2 days per week. 2

First-Line Preventive Medications

• Beta-blockers (propranolol 80–240 mg/day, metoprolol 100–200 mg/day) are first-line agents, particularly beneficial if hypertension coexists. 1, 8, 2
• Topiramate 50–100 mg/day is first-line, especially beneficial in obese patients; monitor for cognitive side effects (word-finding difficulty, memory impairment). 1, 8
• Candesartan 16–32 mg/day offers effectiveness with good tolerability, particularly in hypertensive patients. 1, 8

Second-Line Preventive Medications

• Amitriptyline 30–150 mg/day at bedtime or nortriptyline are preferred when comorbid depression, anxiety, or sleep disturbances are present. 1, 8
• Venlafaxine (75–150 mg/day), escitalopram, or paroxetine provide dual benefit for migraine prevention and vasomotor symptoms (hot flashes), making them particularly useful in perimenopausal women. 3
• Gabapentin (300–900 mg/day) can reduce both migraine frequency and vasomotor symptoms. 3
• Valproic acid is absolutely contraindicated in women of childbearing potential due to teratogenic risk. 8, 2

Third-Line Options for Refractory Cases

• CGRP monoclonal antibodies (erenumab 70 or 140 mg subcutaneous monthly, fremanezumab 225 mg monthly or 675 mg quarterly, galcanezumab, eptinezumab 100 or 300 mg IV quarterly) should be considered when first- and second-line agents fail. 1
• OnabotulinumtoxinA 155–195 units to 31–39 sites every 12 weeks is the only FDA-approved therapy for chronic migraine (≥15 headache days/month). 1, 2

Treatment Duration and Assessment

• Assess efficacy of oral preventive medications after 2–3 months at therapeutic dose. 1
• For CGRP monoclonal antibodies, assess efficacy after 3–6 months; for onabotulinumtoxinA, assess after 6–9 months. 1
• Consider pausing preventive treatment after 6–12 months of successful control to determine if therapy can be stopped. 1

Hormonal Considerations

Hormone Replacement Therapy (HRT)

If HRT is pursued for severe climacteric symptoms, continuous combined estrogen-progesterone therapy (rather than cyclic) is mandatory to prevent estrogen withdrawal and migraine exacerbation. 4, 5, 7, 6

• Transdermal estradiol (50 mcg/day patch twice weekly or once weekly) is strongly preferred over oral formulations because it maintains constant blood hormone levels and avoids first-pass hepatic metabolism. 4, 5, 7
• Oral estrogen (if transdermal is unavailable) should be given as half the daily dose every 12 hours to maintain optimal stability. 5
• Add medroxyprogesterone acetate 2.5 mg every evening or micronized progesterone 100 mg every evening in women with an intact uterus to prevent endometrial hyperplasia. 5
• Tibolone may be useful when analgesic overuse is documented. 7

Critical HRT Warnings

• Cyclic HRT can exacerbate migraine in women susceptible to estrogen fluctuations, even in those who experienced improvement after natural menopause. 5, 6
• Estrogen replacement therapy in patients with migraine with aura may increase ischemic stroke risk in a dose-dependent manner; use the lowest effective dose and counsel patients on potential adverse events. 3
• HRT often results in worsening of migraine and carries potential for increased cardiovascular and ischemic stroke risk. 3
• Concomitant use of a progestogen decreases the risk of endometrial hyperplasia with estrogen replacement therapy. 3

When to Avoid HRT

• Do not initiate HRT in women with migraine with aura who have additional vascular risk factors (smoking, hypertension, diabetes, obesity, age >35 years). 3
• Standard contraindications to HRT (history of breast cancer, venous thromboembolism, active liver disease, unexplained vaginal bleeding) apply to women with migraine. 5

Non-Pharmacological Strategies

• Biobehavioral therapy (relaxation techniques, stress management, biofeedback) can be as effective as pharmacological approaches and should be combined with medication. 1, 3
• Acupuncture has supporting evidence for migraine prevention, though not superior to sham acupuncture. 1, 3
• Aerobic exercise and yoga may reduce both headache and vasomotor symptoms. 3
• Vitamin E and black cohosh may be helpful in reducing headache and/or vasomotor symptoms. 3
• Maintain regular sleep schedule, limit caffeine to ≤200 mg/day consumed before noon, avoid excessive alcohol and nicotine, eat well-balanced meals, and maintain adequate hydration. 1

Common Pitfalls to Avoid

• Do not abandon preventive therapy prematurely; efficacy takes 2–3 months for oral agents to establish. 1
• Failure of one preventive treatment does not predict failure of other drug classes. 1
• Do not allow patients to increase frequency of acute medication use in response to treatment failure; instead transition to preventive therapy. 2
• Avoid substituting opioids or butalbital compounds as rescue medications during medication withdrawal. 2
• Do not prescribe cyclic HRT to perimenopausal women with migraine; continuous therapy is mandatory. 5, 6